The Acute Effect of Grains of Paradise (Aframomum Melegueta) on REE

NCT ID: NCT03894137

Last Updated: 2019-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-31

Study Completion Date

2020-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Grains of paradise (Aframomumu melegueta) (GP), also known as Guinea pepper or Alligator pepper, belongs to the Zingiberaceae family, which is native to West Africa. GP seeds are used as a spice and also have wide-ranging ethnobotanical uses. GP seeds are very rich in non-volatile pungent compounds such as 6-paradol, 6-gingerol, 6-shogaol and related compounds. This feature may equip them with the power to activate the Sympathetic Nervous System and thereby increase EE, which has been demonstrated in rodents. Research suggest that ingestion of GP extract can result in sustained elevation of EE and a consequent reduction in body fat. Thus, there is some evidence that GP may have a potential thermogenic effect that could be useful as part of a weight loss treatment. However, there is no information on whether GP has the potential of improving and prolonging the thermogenic effects of bioactives known to elevate fatty acid mobilization and subsequent fat oxidation. This proposal will fill a void in the literature by testing for the first time in healthy, normal weight, human volunteers whether the ingestion of GP in combination with a commercially available complex containing caffeine, green tea, and forskolin has an enhanced acute effect on REE, the largest and most stable component of EE, as well as the ratio of fat:carbohydrate oxidation. This project will provide pilot data to support larger studies such as prospective studies and studies to compare the thermogenic effect with currently available compounds.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Grains of Paradise

Group Type EXPERIMENTAL

Grains of Paradise (Aframomum Melegueta)

Intervention Type DIETARY_SUPPLEMENT

This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism

Placebo

Group Type PLACEBO_COMPARATOR

Grains of Paradise (Aframomum Melegueta)

Intervention Type DIETARY_SUPPLEMENT

This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Grains of Paradise (Aframomum Melegueta)

This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 18-65 years
* Men and women
* Able to provide written consent in English
* A body mass index between 18.5 and 30 kg/m2

Exclusion Criteria

* Current smoker
* Claustrophobia
* Use of any prescribed or over-the-counter medication affecting metabolism
* Suffering from cardiac, hepatic, renal, pulmonary, endocrine or hematological disease
* Currently pregnant or breastfeeding
* Consuming more than 300mg of caffeine per day
* Consuming more than 2 alcoholic beverages per day.
* Performing more than 3 hrs/week of strenuous exercise
* Weight loss of more than 5% of body weight over the past 6 months
* Not willing to abstain from alcohol, caffeine and exercise for 24hr before each test day.
* Suffering from heartburn or a sensitivity to pungent compounds in foods
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

George Mason University

OTHER

Sponsor Role collaborator

Plexus Worldwide

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1355504-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Improving Sleep In Midlife Women
NCT07337915 NOT_YET_RECRUITING NA
Almond for Physical Performance
NCT04787718 COMPLETED NA